SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED has initiated a registrational Phase III trial for HMPL-760, a…

HUTCHMED (China) Limited · PRESS-RELEASE filed Mar 22, 2026 at 20:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Mar 22, 2026 at 20:00 ET

HUTCHMED has initiated a registrational Phase III trial for HMPL-760, a third-generation BTK inhibitor, in combination with R-GemOx for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China. The trial follows promising Phase II results showing improved response and survival outcomes, positioning HMPL-760 as a potential best-in-class therapy targeting both wild-type and C481S-mutated BTK.

  • HUTCHMED initiated a registrational Phase III trial of HMPL-760 in combination with R-GemOx for relapsed/refractory DLBCL in China.
  • First patient dosed on March 20, 2026; trial is randomized, double-blind, and placebo-controlled.
  • Primary endpoints are progression-free survival (PFS) and overall survival (OS); trial will enroll ~240 patients.
  • Phase II data (NCT06601504) showed improved ORR, CRR, PFS, and OS with manageable safety profile.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access